Beximco Pharmaceuticals (LSE:BXP) Total Equity: £389.8 Mil (As of Mar. 2026)


LSE:BXP Beximco Pharmaceuticals PLC LSE:BXP
68 GF Score
Price £0.45
GF Value £0.39
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Beximco Pharmaceuticals Total Equity?

Beximco Pharmaceuticals LSE:BXP 68 Total Equity is £389.8 Mil as of Mar. 2026. GuruFocus rates LSE:BXP with a GF Score™ of 68/100 and a GF Value™ of £0.39 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Beximco Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was £389.8 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Beximco Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Total Equity Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 227.21 271.43 289.57 315.62 347.13

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 347.13 361.73 376.11 389.76
LSE:BXP
68GF Score
Beximco Pharmaceuticals PLC LSE:BXP
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beximco Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Beximco Pharmaceuticals's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=445.411-98.284
=347.1

Beximco Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=478.759-88.995
=389.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of £389.8 Mil mean?
Beximco Pharmaceuticals (LSE:BXP) has a Total Equity of £389.8 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' Total Equity too high?
Beximco Pharmaceuticals' current Total Equity is £389.8 Mil. Overall, Beximco Pharmaceuticals has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Total Equity compare to ZTS and UTHR?
Beximco Pharmaceuticals' Total Equity of £389.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Total Equity is £389.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (LSE:BXP) is currently considered Modestly Overvalued. The stock's GF Value™ is £0.39, compared to a current price of £0.45 — trading 15.4% above its estimated fair value. The current Total Equity is £389.8 Mil. Beximco Pharmaceuticals' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Beximco Pharmaceuticals (LSE:BXP), the current Total Equity is £389.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beximco Pharmaceuticals (LSE:BXP) Overvalued in 2026?

Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued. The current stock price of £0.45 is trading 15.4% above its estimated GF Value™ of £0.39. GuruFocus considers Beximco Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for LSE:BXP:

  • Total Equity: £389.8 Mil
  • GF Value™: £0.39 vs. price of £0.45 (15.4% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the LSE:BXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
68GF Score

Get the complete analysis for LSE:BXP

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.45
Price
£0.39
GF Value